AZ reaffirms whole-hog API outsourcing

Remember last fall when AstraZeneca EVP David Smith said the company was looking to outsource most of its manufacturing? And the ensuing outcry had AstraZeneca's PR operation backpedaling like crazy?

Well, after AstraZeneca settled its differences with Ranbaxy Laboratories, Smith's boss affirmed a big chunk of those outsourcing plans. In a conference call about the Ranbaxy deal, CEO David Brennan (photo) said that AstraZeneca wants to outsource all API manufacturing within 10 years. AstraZeneca, remember, agreed to hand over manufacturing of Nexium's active ingredient to Ranbaxy as part of the settlement. "This move is absolutely consistent with our supply chain strategy," Brennan said. "We have long-term plans to exit all API production over the next five to 10 years."

While that's not exactly "most" of AstraZeneca's manufacturing, it is a sizable shift. Stay tuned.

- see the article in Contract Pharma

ALSO: India's Dr. Reddy's laboratories agreed to buy BASF's contract manufacturing plant in Shreveport, LA, which focuses on turning out finished prescription and OTC liquids, tablets, and creams for the U.S. market. Terms weren't disclosed, but the business brought in $43 million for BASF last year. Report

Related Articles:
AstraZeneca to outsource manufacturing
AstraZeneca: Just a bit of outsourcing
Forecast: BioPharma outsourcing will grow '08

Suggested Articles

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.

After Merck and Bayer's vericiguat scored in a heart failure trial, you'd expect potential rivals to brace themselves. Not so for Novartis'…